Current Report Filing (8-k)
18 January 2023 - 10:04PM
Edgar (US Regulatory)
0001860657 false 0001860657 2023-01-13
2023-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2023
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in our charter)
|
Delaware |
|
001-41160 |
|
87-2147982 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.)
|
|
24 School Street,
2nd Floor,
Boston,
MA
|
|
02108 |
| (Address of Principal Executive
Offices) |
|
(Zip
Code) |
(401)
426-4664
(Registrant’s telephone number, including area code)
Not
applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each
class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
Common Stock, par value $0.0001 per share |
|
ALLR |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
As of January 13, 2023, the Company had 18,367,757 shares of common
stock outstanding. Since December 2021, the Company has issued
10,291,933 shares of common stock as a result of exercise of
conversions of 6,965 shares of Series A Preferred Stock. As of
January 13, 2023, there were 13,035 shares of Series A Preferred
Stock issued and outstanding.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
Allarity Therapeutics, Inc. |
| |
|
| |
By: |
/s/ James G. Cullem |
| |
|
James G. Cullem
Chief Executive Officer
|
| |
|
|
| Dated: January 17, 2023 |
|
|
2
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Feb 2023 to Mar 2023
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Mar 2022 to Mar 2023
